在多发性骨髓瘤中,NT157通过准IRS和STAT3/5信号来表现出抗瘤作用
Gustavo Nery de Queiroz1, Keli Lima2, Livia Bassani Lins de Miranda1
1Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Hematology, transfusion and cell therapy
|March 24, 2024
概括
这项研究探讨了多发性骨髓瘤 (MM) 中的IGF1/IGF1R途径,发现一种新型抑制剂NT157有效地向MM细胞. NT157通过降低细胞活力和促进细胞亡,有望增强MM疗法.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 多发性骨髓瘤 (MM) 是一种经常出现的血液性恶性瘤,缺乏确定的治疗方法.
- 胰岛素样生长因子1 (IGF1) /IGF1受体 (IGF1R) 轴在MM细胞存活,增殖,迁移和患者的结果中发挥着关键作用.
- 目前MM的治疗策略需要新的方法来克服耐药性和复发.
研究的目的:
- 研究IGF1/IGF1R信号轴在多发性骨髓瘤中的作用.
- 评估一种新型抑制剂NT157的疗效,该抑制剂向MM中的IGF1/IGF1R途径.
- 阐明NT157在MM中的抗癌作用背后的分子机制.
主要方法:
- 在MM患者和健康捐赠者中对IGF1R信号相关基因表达的比较分析.
- 在MM细胞系中评估IGF1R相关蛋白质表达.
- 基因依赖性分析以确定关键信号组件.
- 在体外评估NT157对MM细胞活力,增殖,细胞周期和亡的影响.
- 对NT157对关键细胞内信号分子 (IRS,STAT,RPS6) 和瘤基因/瘤抑制剂的影响的分析.
主要成果:
- 在MM患者和健康捐赠者之间观察到IGF1R信号基因表达的显著差异.
- 毫米细胞系表现出IGF1R相关蛋白质的各种表达模式.
- NT157对MM细胞活力,克隆生长,细胞循环进展和生存产生显著的抑制作用.
- NT157降低了IRS2的表达,并抑制了STAT3,STAT5和RPS6的激活.
- NT157调节瘤基因和瘤抑制剂,促进抑制瘤的分子特征.
结论:
- 在多重髓瘤细胞中,IGF1/IGF1R/IRS信号轴被差异激活.
- 在MM中,NT157有效地针对IGF1/IGF1R/IRS途径中的关键分子参与者.
- NT157在MM细胞中表现出强烈的抗增殖和亲子亡作用,这表明它有可能成为MM的新型治疗剂.
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K


